| Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised … SN Faust, R Haynes, CE Jones, N Staplin, E Whittaker, T Jaki, E Juszczak, ... The Lancet Child & Adolescent Health 8 (3), 190-200, 2024 | 6 | 2024 |
| Health-related quality of life and long-term joint damage in people with severe haemophilia A in Brazil J Evans, T Burke HAEMOPHILIA 30, 108-108, 2024 | | 2024 |
| Characterization of Tumor Responses in Patients With Unresectable Hepatocellular Carcinoma Treated With Lenvatinib in the Phase 3 Randomized Trial, REFLECT RS Finn, S Qin, F Piscaglia, TRJ Evans, JJ Knox, C López López, Z Ramji, ... | | 2024 |
| Recruitment and baseline data of the Aging and Cognitive Health Evaluation in Elders (ACHIEVE) study: A randomized trial of a hearing loss intervention for reducing cognitive … NS Reed, L Gravens‐Mueller, AR Huang, AM Goman, CM Mitchell, ... Alzheimer's & Dementia: Translational Research & Clinical Interventions 10 …, 2024 | 1 | 2024 |
| Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial PK Judge, N Staplin, KJ Mayne, C Wanner, JB Green, SJ Hauske, ... The Lancet Diabetes & Endocrinology 12 (1), 51-60, 2024 | 9 | 2024 |
| Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial O Abani, A Abbas, F Abbas, J Abbas, K Abbas, M Abbas, S Abbasi, ... The Lancet Diabetes & Endocrinology 11 (12), 905-914, 2023 | 12 | 2023 |
| 131P Safety and clinical efficacy of roginolisib (IOA-244): The first oral allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3Kδ) AM Di Giacomo, M Simonelli, F Santangelo, G Amato, E Simonetti, ... Immuno-Oncology and Technology 20, 2023 | | 2023 |
| Abstract B039: A phase 1/2 study of dendrimer-enhanced (DEP) SN38 (SN38-SPL9111/DEP irinotecan) in patients with advanced solid tumours J Liu, AR Minchom, A Greystoke, TRJ Evans, D Sarker, AM Joshua, ... Molecular Cancer Therapeutics 22 (12_Supplement), B039-B039, 2023 | | 2023 |
| Multiorgan MRI findings after hospitalisation with COVID-19 in the UK (C-MORE): a prospective, multicentre, observational cohort study B Raman, C McCracken, MP Cassar, AJ Moss, L Finnigan, AHA Samat, ... The Lancet Respiratory Medicine 11 (11), 1003-1019, 2023 | 13 | 2023 |
| LBA100 CUP-ONE trial: A prospective double-blind validation of molecular classifiers in the diagnosis of cancer of unknown primary and clinical outcomes HS Wasan, J Wang, EME McCartney, H Soifer, K Treuner, Y Zhang, ... Annals of Oncology 34, S1339, 2023 | 1 | 2023 |
| 1107P BRAF mutation status does not impact outcomes with tebentafusp in advanced cutaneous melanoma AN Shoushtari, MR Middleton, O Hamid, F Meier, T Bauer, AKS Salama, ... Annals of Oncology 34, S667-S668, 2023 | | 2023 |
| Effects of sleep disturbance on dyspnoea and impaired lung function following hospital admission due to COVID-19 in the UK: a prospective multicentre cohort study C Jackson, ID Stewart, T Plekhanova, PS Cunningham, AL Hazel, ... The Lancet Respiratory Medicine 11 (8), 673-684, 2023 | 15 | 2023 |
| Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open … O Abani, A Abbas, F Abbas, J Abbas, K Abbas, M Abbas, S Abbasi, ... The Lancet 401 (10387), 1499-1507, 2023 | 21 | 2023 |
| Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial MA Tempero, U Pelzer, EM O'Reilly, J Winter, DY Oh, CP Li, G Tortora, ... Journal of Clinical Oncology 41 (11), 2007-2019, 2023 | 52 | 2023 |
| Evaluating the measures in patient-reported outcomes, values and experiences (EMPROVE study): a collaborative audit of PROMs practice in orthopaedic care in the United Kingdom A Matthews, JP Evans, ... The Annals of The Royal College of Surgeons of England 105 (4), 357-364, 2023 | 2 | 2023 |
| Development of a core descriptor set for Crohn's anal fistula ENiGMA CODE Collaborators, KM Williams, S Lamidi, PO Coe, ... Colorectal Disease 25 (4), 695-706, 2023 | 5 | 2023 |
| 119P Long-term safety evaluation of roginolisib (formerly IOA-244), a highly selective phosphoinositide 3-kinase inhibitor delta (PI3Kδ), in a phase I first-in-human (FIH) study AM Di Giacomo, P Mason, R Snijder, A Abdul-Ahad, M Lahn, ... ESMO Open 8 (1), 2023 | | 2023 |
| 79MO Developing international consensus-driven SPIRIT and CONSORT extensions for early phase dose-finding clinical trials: The DEFINE (DosE FIndiNg Extensions) study O Solovyeva, M Dimairo, C Weir, JS de Bono, A Bedding, AW Chan, ... ESMO Open 8 (1), 2023 | | 2023 |
| Systematic review and meta-analysis of the diagnostic effectiveness of positron emission tomography-computed tomography versus magnetic resonance imaging in the post-treatment … Y Zhu, O McLaren, J Hardman, J Evans, R Williams The Journal of Laryngology & Otology 137 (1), 22-30, 2023 | 2 | 2023 |
| SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination F Liew, S Talwar, A Cross, BJ Willett, S Scott, N Logan, MK Siggins, ... EBioMedicine 87, 2023 | 72 | 2023 |
